For heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis…. ANDA 202471, held by Mylan Institutional. Bivalirudin.
As of Nov 16, 2026, ANDA 202471 (Bivalirudin), held by Mylan Institutional, was first approved by FDA on Jun 1, 2018, with 1 approved supplement and 0 published complete response letters.
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Rx |
| Sep 23, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 1, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters